Lurasidone + Placebo

Phase 3Completed

0 views this week 0 watching⚡ Active

Interest: 40/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Major Depressive Disorder With Mixed Features

Conditions

Major Depressive Disorder With Mixed Features

Trial Timeline

Sep 1, 2011 → Oct 1, 2014

NCT ID

NCT01421134

About Lurasidone + Placebo

Lurasidone + Placebo is a phase 3 stage product being developed by Sumitomo Pharma for Major Depressive Disorder With Mixed Features. The current trial status is completed. This product is registered under clinical trial identifier NCT01421134. Target conditions include Major Depressive Disorder With Mixed Features.

What happened to similar drugs?

20 of 20 similar drugs in Major Depressive Disorder With Mixed Features were approved

Approved (20) Terminated (0) Active (0)

✅Mirtazapine TabletsSun PharmaceuticalApproved

✅DuloxetineEli LillyApproved

✅duloxetineEli LillyApproved

✅DuloxetineEli LillyApproved

✅duloxetine hydrochlorideEli LillyApproved

✅DuloxetineEli LillyApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (5)

NCT ID	Phase	Status	Start	Completion	Indication
NCT02046369	Phase 3	Completed	Mar 1, 2014	Oct 1, 2016	Bipolar I Depression
NCT01421134	Phase 3	Completed	Sep 1, 2011	Oct 1, 2014	Major Depressive Disorder With Mixed Features
NCT01358357	Phase 3	Completed	Jun 1, 2011	Apr 1, 2015	Bipolar I Disorder
NCT01284517	Phase 3	Completed	Nov 1, 2010	Aug 1, 2012	Bipolar Depression
NCT00088634	Phase 2	Completed	May 1, 2004	Dec 1, 2004	Schizophrenia

Competing Products

20 competing products in Major Depressive Disorder With Mixed Features

See all competitors

Product	Company	Stage	Hype Score
Duloxetine Hydrochloride	Eli Lilly	Pre-clinical	26
LY2216684	Eli Lilly	Phase 1	29
LY2216684	Eli Lilly	Phase 1	29
Duloxetine	Eli Lilly	Phase 3	40
LY2216684 + Digoxin	Eli Lilly	Phase 1	29
Duloxetine + Paroxetine	Eli Lilly	Phase 3	40
Duloxetine + placebo	Eli Lilly	Phase 3	40
LY2216684 + Placebo + Escitalopram	Eli Lilly	Phase 2	35
FK949E	Astellas Pharma	Phase 1	29
quetiapine extended release (XR) + Placebo	Astellas Pharma	Phase 2	35
FK949E	Astellas Pharma	Phase 1	29
FK949E	Astellas Pharma	Phase 1	29
FK949E	Astellas Pharma	Phase 1	29
Mirtazapine Tablets	Sun Pharmaceutical	Approved	43
ONO-2333Ms Experimental 2 + Placebo + ONO-2333Ms Experimental 1	Ono Pharmaceutical	Phase 2	35
ONO-1110 + Placebo	Ono Pharmaceutical	Phase 2	39
Pramipexole ER + Escitalopram	Cipla	Phase 2	42
LY2216684 + Sertraline	Eli Lilly	Phase 1	29
LY2216684 + Placebo + Lorazepam	Eli Lilly	Phase 1	29
LY2216684 + SSRI	Eli Lilly	Phase 3	40